Improving diversity in clinical trials is not just the right thing to do, it is necessary for better science, more representative outcomes, and increased health equity. Historically, clinical trials have been shown to recruit disproportionately large percentages of White participants. These skewed participant populations raise concerns about the generalizability of trial results to underrepresented non-White participants, specifically Black participants, and barriers to minority participation in clinical trials.

In our new research report, we set forth to assess the current state of racial diversity beyond the FDA Snapshot, using Medidata’s industry-leading clinical trial data repository. This analysis covers:

• 972,773 trial participants
• 4,003 global trials
• Various levels of data granularity including global, US, TA, and site level analysis

This latest analysis uncovers variation previously masked by aggregate enrollment estimates of Black enrollment in clinical trials.